Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...

对于此次收购，德国默克执行董事会主席兼首席执行官 Belén Garijo 表示：“SpringWorks ...

Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

默克集团（Merck KGaA, Darmstadt, Germany）宣布将以每股47美元的现金收购SpringWorks ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...

Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire ...

智通财经APP获悉，据《华尔街日报》最新报道，德国默克集团(Merck KGaA)当前非常接近达成一项大约35亿美元的协议，收购癌症以及罕见病药物知名开发商 SpringWorks Therapeutics(SWTX.US)，消息传出后 ...

SpringWorks总部位于美国康涅狄格州的斯坦福德，于2019年在纽约上市。该公司开发治疗癌症和罕见肿瘤的药物，目前在市场上有两种产品：用于治疗硬纤维瘤的Ogsiveo，2024年销售额为1.72亿美元，以及Gomekli，今年2月获批用于治疗以 ...